Cellceutix has been overlooked on the market because of its unknown status as a biotechnology company. It trades on the OTC which lacks a lot of coverage, which is part of the reason it is not well known. We believe that upcoming trials along with catalysts/presentations could lead the share price to rise in 2014 as people analyze the true value of the company. We believe that Cellceutix is a good long term stock to own in 2014 and beyond!
There are so many biotech companies out there that are looking to create new advances in cancer therapy. There are currently a lot of chemotherapy drugs that leave patients with a lot of toxic side effects. The hope now...
Only subscribers can access this article, which is part of the PRO research library covering 3,612 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: